Based on the key measurements obtained from Biofrontera's financial statements, Biofrontera is not in a good financial situation at this time. It has a very high odds of going through financial crisis in March. As of now, Biofrontera's Accounts Payable is decreasing as compared to previous years. The Biofrontera's current Cash is estimated to increase to about 8.6 M, while Short and Long Term Debt Total is projected to decrease to under 4.2 M.
Cash Flow Balance Sheet Income Statement
Covid
Interest Hikes
Biofrontera Balance Sheet Chart
As of now, Biofrontera's Accounts Payable is decreasing as compared to previous years. The Biofrontera's current Cash is estimated to increase to about 8.6 M, while Short and Long Term Debt Total is projected to decrease to under 4.2 M.
Investors should never underestimate Biofrontera's ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Biofrontera's cash flow, debt, and profitability to make informed and accurate decisions about investing in Biofrontera.
Understanding current and past Biofrontera Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Biofrontera's financial statements are interrelated, with each one affecting the others. For example, an increase in Biofrontera's assets may result in an increase in income on the income statement.
Biofrontera competes with Gelteq Limited, ProPhase Labs, Aytu BioScience, Evogene, and Dogwood Therapeutics. Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts. Biofrontera operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 69 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Comparative valuation techniques use various fundamental indicators to help in determining Biofrontera's current stock value. Our valuation model uses many indicators to compare Biofrontera value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Biofrontera competition to find correlations between indicators driving Biofrontera's intrinsic value. More Info.
Biofrontera is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . As of now, Biofrontera's Return On Equity is decreasing as compared to previous years. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Biofrontera's earnings, one of the primary drivers of an investment's value.
Most indicators from Biofrontera's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Biofrontera current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biofrontera. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.
Today, most investors in Biofrontera Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Biofrontera's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Biofrontera growth as a starting point in their analysis.
Along with financial statement analysis, the daily predictive indicators of Biofrontera help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Biofrontera. We use our internally-developed statistical techniques to arrive at the intrinsic value of Biofrontera based on widely used predictive technical indicators. In general, we focus on analyzing Biofrontera Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Biofrontera's daily price indicators and compare them against related drivers.
Complementary Tools for Biofrontera Stock analysis
When running Biofrontera's price analysis, check to measure Biofrontera's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biofrontera is operating at the current time. Most of Biofrontera's value examination focuses on studying past and present price action to predict the probability of Biofrontera's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biofrontera's price. Additionally, you may evaluate how the addition of Biofrontera to your portfolios can decrease your overall portfolio volatility.